David Gilles

David Gilles worked as the Co-Founder and CTO at Küleon Bioscience, where they focused on developing novel compounds for the treatment of neuropsychiatric disorders. Before that, they were a Consultant at Phase 3 Labs Solutions, specializing in ISO 17025 accreditation, chemical and microbial analytics, and laboratory build-outs for cannabis testing. David also served as the R&D Lab Manager at Biosynthetic Technologies, where they prepared estolides for examination as potential base oils for various applications. Prior to that, they were the VP of Scientific Operations at Spectra Analytical Laboratories dba SteepHill Hawaii, where they oversaw the creation and modification of SOPs and regulatory operations for sample testing.

David Gilles completed their Bachelor of Science in Chemistry at the University of Hawaii at Manoa from 2007 to 2012. David then pursued a Master of Science in Organic Chemistry at the same university from 2012 to 2016.